
Lucknow (Uttar Pradesh) [India], November 18: Chandan Healthcare Limited (NSE – CHANDAN), – Chandan Healthcare Limited, one of the leading players in Diagnostic sector having Pan India presence, has announced its unaudited Financial Results for Q2 & H1 FY27.
Q2 FY27 Standalone Key Financial Highlights
H1 FY27 Standalone Key Financial Highlights
Note: Chandan Healthcare Limited divested its entire stake in Chandan Pharmacy Limited during Q2 FY27. The Standalone results therefore reflect the Company’s diagnostics business and are the basis for comparison going forward. PAT, PAT margin and EPS for Q2 FY27 and H1 FY27 include a one-time exceptional gain of ₹10.23 Cr (net of tax; ₹12.03 Cr gross) on the sale of the Company’ s investment in equity shares of Chandan Pharmacy Limited. EBITDA and PAT margins are calculated on Total Income. EPS is basic EPS. Comparative figures are as presented in the results filed with the exchange.
For more details, visit the company’s website: https://chandandiagnostic.com/
Commenting on the financial performance, Mr. Amar Singh, Promoter and Chairman & Managing Director of Chandan Healthcare Limited, said, “Q2 FY27 was a strong quarter for us. Consolidated total income grew 48.70% year-on-year and EBITDA grew 63.35%, with EBITDA margin up 331 basis points. For the half year, total income grew 35.69% and EBITDA grew 49.03%. The growth came from our diagnostics business as the franchise network scaled up.
Our franchise network grew from 264 centres at the end of June to 685 centres at the end of September. Franchising lets us widen our reach in a capital-efficient manner, and we continue to work towards 1,000 franchise centres. We also added Comprehensive Diagnostic Centres, Diagnostic Centres and Labs of our own during the quarter.
In August, the Board approved the sale of our entire stake in Chandan Pharmacy Limited, and the transaction was completed during the quarter. Pharmacy was a low-margin business, with over 70% of its revenue coming from B2B supply. The sale lets us put management time and capital behind diagnostics, which earns materially higher margins, and the proceeds will go towards new diagnostic centres. PAT for the quarter includes a one-time gain from the sale, so profit growth should be read with that in mind.
For the rest of FY27, we will keep adding franchise centres towards the 1,000 mark, open owned centres in attractive markets, scale our work with Jeena Sikho hospitals and clinics and grow the B2G business. We will put capital where returns are higher, which means new diagnostic centres, and keep improving utilisation across the network.”
Divestment of Entire Stake in Chandan Pharmacy Limited Sharpens Focus on Core Diagnostics
Franchise Network Scales to 685 Centres, Target 1000 franchises by FY27
Entry into Ghaziabad Through Acquisition of Ansh Diagnostics Units
Chandan Healthcare Limited, established in 2003, is one of India’s leading providers of diagnostic services and a key entity of the Chandan Group. The Company delivers a comprehensive range of pathology and radiology services through its expanding network across India.
As on September 30, 2026, the Company’s network comprises 685 franchise centres, 25 Comprehensive Diagnostic Centres, 19 Diagnostic Centres, 25 Diagnostic Labs and 16 Radiology Labs, strengthening its presence across urban, semi-urban and emerging markets. Its diagnostic portfolio comprises more than 3,000 pathology tests and 500+ radiology tests, including blood tests, X-ray, ECG, Ultrasound, CT scan, MRI and several other specialized diagnostic investigations. The Company’s network includes NABL and NABH accredited pathology laboratories and radiology centres, reflecting its commitment to delivering reliable, high-quality diagnostic services.
Chandan Healthcare operates through a diversified business model comprising B2C (Retail Customers), B2B (Institutional & Corporate Clients) and B2G (Government PPP Contracts), providing a balanced and scalable revenue profile while catering to a wide spectrum of healthcare needs. The Company was listed on the NSE Emerge platform on February 17, 2025.
During FY26, The Company reported Total Income of ₹280.67 Cr, EBITDA of ₹56.84 Cr and Profit After Tax (PAT) of ₹27.06 Cr, reflecting its continued operational growth and financial strength.
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
German cabinet approves first financial literacy strategy
By Maria Martinez BERLIN, Nov 18 (Reuters) - The German cabinet approved on Wednesday its…
Britain's Prince William visits Bollywood studio, watches dancers
By Shilpa Jamkhandikar MUMBAI, Nov 18 (Reuters) - Britain's Prince William watched Bollywood dances and…
US senators warn White House that AI-enabled cyber threats are outpacing defenses
By Gnaneshwar Rajan Nov 18 (Reuters) - A pair of US senators on Wednesday warned…